Treace Medical Concepts (NASDAQ:TMCI) Posts Earnings Results, Beats Expectations By $0.06 EPS

Treace Medical Concepts (NASDAQ:TMCI) announced its quarterly earnings data on Friday. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.06, FiscalAI reports. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. The business had revenue of $48.25 million for the quarter, compared to analyst estimates of $47.80 million.

Here are the key takeaways from Treace Medical Concepts’ conference call:

• Q3 revenue fell 4% year over year to $48.3 million, primarily due to lower-priced product mix and fewer bunion kits sold. Excluding stocking-distributor sales, revenue grew mid-single digits, while procedure volumes increased at a double-digit rate.
• Treace narrowed its 2026 revenue outlook to $206 million–$210 million, still implying a 1%–3% annual decline, and expects to return to revenue growth in Q4. Management attributed the expected improvement to higher procedure volumes, easier comparisons on product mix, and contributions from new launches.
• Profitability and cash trends improved: Q3 adjusted EBITDA was positive $0.3 million versus a $2.6 million loss a year earlier, operating expenses fell 10%, and year-to-date cash usage declined 53%. Full-year adjusted EBITDA is still expected to be a loss of $1 million–$2 million.
• The company is expanding beyond its core bunion products with 2026 launches it estimates add about $700 million of U.S. addressable market; nearly 45% of Lapiplasty surgeons had adopted at least one of its newer bunion systems by Q3. Management sees broader product adoption as a growth opportunity, though it cautioned that newer products may keep average revenue per case below historical levels.

Treace Medical Concepts Stock Down 3.6%

TMCI stock traded down $0.15 during mid-day trading on Friday, reaching $4.03. The company had a trading volume of 596,717 shares, compared to its average volume of 224,524. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.90 and a quick ratio of 1.95. The stock has a 50 day simple moving average of $4.39 and a two-hundred day simple moving average of $3.28. The company has a market capitalization of $262.11 million, a price-to-earnings ratio of -4.33 and a beta of 1.59. Treace Medical Concepts has a 52 week low of $1.17 and a 52 week high of $5.25.

Insider Activity

In related news, CEO John Treace acquired 11,000 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were bought at an average price of $4.34 per share, for a total transaction of $47,740.00. Following the purchase, the chief executive officer directly owned 7,404,383 shares in the company, valued at approximately $32,135,022.22. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 55,944 shares of company stock worth $246,841. Corporate insiders own 23.42% of the company’s stock.

Key Stories Impacting Treace Medical Concepts

Here are the key news stories impacting Treace Medical Concepts this week:

• Positive Sentiment: Third-quarter revenue was $48.25 million, above the $47.80 million consensus, while its loss of $0.19 per share was narrower than estimates of $0.25–$0.26. The per-share loss also improved from $0.26 a year earlier. Third-quarter results
• Positive Sentiment: Treace announced the first surgical cases using its Tailorplasty MIS Tailor’s Bunion Correction System. The new offering expands its product range and could open access to additional procedures, although the announcement did not quantify expected sales or adoption. Tailorplasty announcement
• Neutral Sentiment: 2026 revenue guidance is $206 million to $210 million, a range that includes the $207.6 million analyst consensus. The midpoint is slightly above consensus, but the outlook is broadly in line with expectations. Financial results and guidance
• Negative Sentiment: Despite the quarterly beat, TMCI continues to post losses, leaving profitability a key concern for investors. Q3 loss and revenue report

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TMCI. Truist Financial lifted their price target on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the company a “hold” rating in a research note on Monday, August 10th. Weiss Ratings upgraded shares of Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.00.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of bunion deformities and other conditions affecting the foot and ankle. The company’s technologies are designed to address the underlying structural causes of bunions and support more stable correction than traditional surgical approaches.

Treace’s primary product is the Lapiplasty 3D Bunion Correction System, which is used by foot and ankle surgeons to correct bunions in three dimensions.